In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

A recent study revealed that individuals taking weight-loss drugs, including renowned GLP-1s, may significantly regain weight ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny.

The shipments have propelled Ireland, a country of only 5.4 million people, to the second-largest goods-trade imbalance with ...